10/28/15 - 10:09 AM EDT
Gilead's hepatitis C drugs are probably the best example of the innovation in medicine we want the biotech industry to strive for when developing new products.
10/27/15 - 04:52 PM EDT
Amgen will market the new drug under the brand name Imlygic. Last Friday, Imlygic also won support from a committee of European drug reviewers.
10/27/15 - 10:01 AM EDT
Merck will conduct an interim analysis before the end of the year of a large, phase III study investigating its cholesterol-lowering pill anacetrapib.
10/27/15 - 06:05 AM EDT
BioBlast paints a very optimistic picture of Cabaletta's potential as an effective treatment for OPMD, but the data announced Tuesday are scant, cherry-picked and hardly conclusive.
10/26/15 - 11:29 AM EDT
Two Valeant investors, one long, the other short, offer their views for what happens to the stock in the months ahead.
10/23/15 - 11:55 AM EDT
Whether the allegations against Valeant are true or not, they shouldn't be tainting most other biotech and drug stocks. That's because Valeant is in its own unique universe.
10/22/15 - 03:50 PM EDT
Investors are totally overreacting to what might be a small hit to Abbvie's hepatitis C revenue.
10/22/15 - 12:18 PM EDT
British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.
10/21/15 - 01:46 PM EDT
Biotech is a high-growth industry fueled by scientific innovation. The snapshot of Biogen Wednesday lacks the biotech buzz for which investors are willing to pay a premium.
10/21/15 - 08:00 AM EDT
The company raised earnings and revenue guidance modestly for the remainder of the year due to the cost savings from the restructuring.